

Suppl Fig 1. Distribution of BRAFV600E (pg) in plasma (Suppl Fig 1a) and serum (Suppl Fig 1b) by M1 stage. Distribution of BRAF expression serum (pg) by metastatic status. No significant differences, unless there is a trend to higher pg in more advanced stage.

Stage	N	BRAF in serum(pg)	
		Mean	Std Dev
M1a	7	0.85857143	2.27156648
M1b	4	0.62500000	1.25000000
M1c	11	1.48172727	2.14627790

Kruskal-Wallis Test	
Chi-Square	0.7825
DF	2
Pr > Chi-Square	0.6762

Stage	N	BRAF in plasma(pg)	
		Mean	Std Dev
M1a	7	2.08000000	3.50258952
M1b	4	1.25000000	1.44337567
M1c	11	4.53000000	8.32817987

Kruskal-Wallis Test	
Chi-Square	0.1593
DF	2
Pr > Chi-Square	0.9234

Suppl Fig 2. Distribution of BRAFV600 (pg) expression in serum (Suppl Fig 2a) and plasma (Suppl Fig 2b) by number of metastatic sites (four sites or more versus three or less).

Number of metastatic sites	N	BRAF in serum (pg)	
		Mean	Std Dev
<=3 metastatic sites	15	0.56733333	1.63755247
>3 metastatic sites	7	2.32842857	2.31893308
Kruskal-Wallis Test			
Chi-Square	4.0872		
DF	1		
Pr > Chi-Square	0.0432		

Number of metastatic sites	N	BRAF in plasma(pg)	
		Mean	Std Dev
<=3 metastatic sites	15	1.47066667	2.53828814
>3 metastatic sites	7	6.76142857	9.94189189
Wilcoxon Two-Sample Test			
Statistic	97.0000		
t Approximation			
One-Sided Pr > Z	0.1132		
Two-Sided Pr > Z	0.2263		
Z includes a continuity correction of 0.5.			

